Lebwohl MG - Search Results

1

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. Hochberg MC, et al. Among authors: lebwohl mg. Semin Arthritis Rheum. 2005 Jun;34(6):819-36. doi: 10.1016/j.semarthrit.2004.11.006. Semin Arthritis Rheum. 2005. PMID: 15942917 Review.

2

Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.

Galadari H, Fuchs B, Lebwohl M. Galadari H, et al. Int J Dermatol. 2003 Mar;42(3):231-7. doi: 10.1046/j.1365-4362.2003.01449.x. Int J Dermatol. 2003. PMID: 12653923 Review.

3

Use of etanercept in the dermatology setting. A review.

Lebwohl MG. Lebwohl MG. Am J Clin Dermatol. 2005;6(1):49-59. doi: 10.2165/00128071-200506010-00006. Am J Clin Dermatol. 2005. PMID: 15675890 Review.

4

No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.

Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, Wallis WJ. Lebwohl M, et al. Arch Dermatol. 2005 Jul;141(7):861-4. doi: 10.1001/archderm.141.7.861. Arch Dermatol. 2005. PMID: 16027301

5

Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.

Wong VK, Lebwohl MG. Wong VK, et al. Among authors: lebwohl mg. Expert Opin Biol Ther. 2005 Nov;5(11):1505-13. doi: 10.1517/14712598.5.11.1505. Expert Opin Biol Ther. 2005. PMID: 16255653 Review.

6

Potential complications associated with the use of biologic agents for psoriasis.

Zeichner JA, Lebwohl M. Zeichner JA, et al. Dermatol Clin. 2007 Apr;25(2):207-13, vii. doi: 10.1016/j.det.2007.01.010. Dermatol Clin. 2007. PMID: 17430757 Review.

7

Combining systemic retinoids with biologic agents for moderate to severe psoriasis.

Smith EC, Riddle C, Menter MA, Lebwohl M. Smith EC, et al. Int J Dermatol. 2008 May;47(5):514-8. doi: 10.1111/j.1365-4632.2008.03470.x. Int J Dermatol. 2008. PMID: 18412874

8

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation. Doherty SD, et al. Among authors: lebwohl mg. J Am Acad Dermatol. 2008 Aug;59(2):209-17. doi: 10.1016/j.jaad.2008.03.023. Epub 2008 May 15. J Am Acad Dermatol. 2008. PMID: 18485527

9

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. Hugh J, et al. J Am Acad Dermatol. 2014 Jan;70(1):168-77. doi: 10.1016/j.jaad.2013.09.020. Epub 2013 Nov 1. J Am Acad Dermatol. 2014. PMID: 24184141 Review.

10

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Whitlock SM, et al. J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. J Am Acad Dermatol. 2018. PMID: 29332708 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results